Literature DB >> 11959767

Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries.

A Boonen1, D van der Heijde, R Landewé, A Spoorenberg, H Schouten, M Rutten-van Mölken, F Guillemin, M Dougados, H Mielants, K de Vlam, H van der Tempel, Sj van der Linden.   

Abstract

OBJECTIVE: To compare work disability, sick leave, and productivity costs due to ankylosing spondylitis (AS) of three European countries.
METHODS: 216 patients with AS from the Netherlands, France, and Belgium participated in a two year observational study. Employment and work disability rates at baseline were adjusted for age and sex. Productivity costs were calculated by both the friction cost method and the human capital approach. The adjusted contributions of country to employment, work disability, and having an episode of sick leave were assessed by logistic regression and the contribution of the country to days of sick leave and costs by Cox proportional hazard analysis.
RESULTS: 209 patients completed the two years' follow up with sufficient data for cost analysis. Adjusted employment was 55% in the Netherlands as compared with 72% in both other countries and only in the Netherlands was it lower than expected in the general population. Adjusted work disability was 41%, 23%, and 9% in the Netherlands, France, and Belgium and in all countries was higher than expected in the general population. In those with a paid job, the mean number of days of sick leave per patient per year because of AS was 19 (range 0-130), six (range 0-77), and nine (range 0-60 ) in the Netherlands, France, and Belgium respectively. Applying the friction cost method to those with a paid job resulted in mean costs per patient per year of 1257 euros (range 0-7356), 428 euros (range 0-5979), and 476 euros (range 0-2354) in the Netherlands, France, and Belgium. Applying the human capital approach to the whole group resulted in mean costs per patient per year of 8862 euros (range 0-46 818), 3188 euros (range 0-43 550), and 3609 euros (range 0-34 320) in the three countries, respectively. After adjusting for sociodemographic and disease characteristics, living in the Netherlands, as compared with both other countries, was associated with a higher chance of being work disabled (odds ratio (OR)=3.82; 95% confidence interval (CI) 1.33 to 11.01), but not with the risk of having an episode of sick leave. Similarly, living in the Netherlands contributed independently to the number of days sick leave (OR=0.65; 95% CI 0.43 to 0.97), a higher amount of friction costs (OR=0.63; 95% CI 0.42 to 0.96), and a higher amount of human capital costs (OR=0.46; 95% CI 0.32 to 0.68).
CONCLUSION: There are remarkable differences in work status and productivity costs between the three European countries. This has implications for the generalisability of health economic studies.

Entities:  

Mesh:

Year:  2002        PMID: 11959767      PMCID: PMC1754093          DOI: 10.1136/ard.61.5.429

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  28 in total

1.  Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in The Netherlands.

Authors:  J L Severens; J Mulder; R J Laheij; A L Verbeek
Journal:  Soc Sci Med       Date:  2000-07       Impact factor: 4.634

Review 2.  How should cost data in pragmatic randomised trials be analysed?

Authors:  S G Thompson; J A Barber
Journal:  BMJ       Date:  2000-04-29

3.  National database of patients visiting rheumatologists in The Netherlands: the standard diagnosis register of rheumatic diseases. A report and preliminary analysis.

Authors:  H S Miedema; S M van der Linden; J J Rasker; H A Valkenburg
Journal:  Br J Rheumatol       Date:  1998-05

4.  Total costs and predictors of costs in patients with systemic lupus erythematosus.

Authors:  N Sutcliffe; A E Clarke; R Taylor; C Frost; D A Isenberg
Journal:  Rheumatology (Oxford)       Date:  2001-01       Impact factor: 7.580

5.  Socioeconomic costs of rheumatic diseases. Implications for technology assessment.

Authors:  D Jonsson; M Husberg
Journal:  Int J Technol Assess Health Care       Date:  2000       Impact factor: 2.188

6.  Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients.

Authors:  A Boonen; A Chorus; H Miedema; D van der Heijde; H van der Tempel; S van der Linden
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

7.  Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers.

Authors:  A Zink; J Braun; J Listing; J Wollenhaupt
Journal:  J Rheumatol       Date:  2000-03       Impact factor: 4.666

Review 8.  Economic burden of rheumatoid arthritis: a systematic review.

Authors:  N J Cooper
Journal:  Rheumatology (Oxford)       Date:  2000-01       Impact factor: 7.580

9.  Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists.

Authors:  K Newhall-Perry; N J Law; B Ramos; M Sterz; W K Wong; K J Bulpitt; G Park; M Lee; P Clements; H E Paulus
Journal:  J Rheumatol       Date:  2000-05       Impact factor: 4.666

10.  Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors.

Authors:  J Braun; M Bollow; G Remlinger; U Eggens; M Rudwaleit; A Distler; J Sieper
Journal:  Arthritis Rheum       Date:  1998-01
View more
  59 in total

Review 1.  Ankylosing spondylitis: introductory comments on its diagnosis and treatment.

Authors:  M A Khan
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

Review 2.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Authors:  J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

3.  Is avoidant coping independent of disease status and stable over time in patients with ankylosing spondylitis?

Authors:  A Boonen; D Van Der Heijde; R Landewé; A Chorus; W Van Lankveld; H Miedema; H Van Der Tempel; S Van Der Linden
Journal:  Ann Rheum Dis       Date:  2004-10       Impact factor: 19.103

4.  A decision chart for assessing and improving the transferability of economic evaluation results between countries.

Authors:  Robert Welte; Talitha Feenstra; Hans Jager; Reiner Leidl
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

5.  Spectrum of ankylosing spondylitis in Portugal. Development of BASDAI, BASFI, BASMI and mSASSS reference centile charts.

Authors:  Fernando M Pimentel-Santos; Ana Filipa Mourão; Célia Ribeiro; José Costa; Helena Santos; Anabela Barcelos; Patricia Pinto; Fátima Godinho; Margarida Cruz; Elsa Vieira-Sousa; Rui André Santos; Sara Rabiais; Jorge Félix; João Eurico Fonseca; Henrique Guedes-Pinto; Matthew A Brown; Jaime C Branco
Journal:  Clin Rheumatol       Date:  2011-10-19       Impact factor: 2.980

Review 6.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 7.  Outcomes in ankylosing spondylitis: what makes the assessment of treatment effects in ankylosing spondylitis different?

Authors:  M M Ward
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

Review 8.  [Burden of illness. First routine report on socio-medical consequences of inflammatory rheumatic disease in Germany].

Authors:  W Mau; W Beyer; I Ehlebracht-König; M Engel; E Genth; B Greitemann; W H Jäckel; A Zink
Journal:  Z Rheumatol       Date:  2008-03       Impact factor: 1.372

9.  Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.

Authors:  Vicente Escudero-Vilaplana; Esther Ramírez-Herráiz; Estefanía Alañón-Plaza; Nicolás Trovato-López; Rosario García-Vicuña; Luis Carreño-Pérez; Alberto Morell-Baladrón; María Sanjurjo-Sáez
Journal:  Int J Clin Pharm       Date:  2015-04-25

10.  High frequencies of HLA-B27 in Chinese patients with suspected of ankylosing spondylitis.

Authors:  Xiang Liu; Yi-Rong Li; Li-Hua Hu; Zhi-Ming Zhou; Feng-Hua Chen; Yong Ning; Qun-Feng Yao
Journal:  Rheumatol Int       Date:  2009-09-23       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.